Boston Scientific Corporation Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before February 3, 2021; click here to submit trade information
LOS ANGELES, Jan. 28, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Boston Scientific Corporation (NYSE: BSX) investors that acquired shares between April 24, 2019 and November 16, 2020. Investors have until February 3, 2021 to seek an active role in this litigation.
Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.
Boston Scientific announced a worldwide recall on November 17, 2020, of all unused inventory of the LOTUS Edge Aortic Valve System, a transcatheter aortic valve replacement product which had been approved by the U.S. Food and Drug Administration ("FDA") in April 2019. Citing "complexities associated with the product delivery system" and the "additional time and investment required to develop and reintroduce an enhanced delivery system," Boston Scientific stated that it had "chosen to retire the entire LOTUS product platform immediately."
On November 17, 2020, Boston Scientific's stock price fell $3.00 per share, or approximately 8%, on this news, to close at $35.03 per share, thereby injuring investors.
It is alleged in this lawsuit that throughout the Class Period, Boston Scientific made misleading and/or materially false statements, as well as failed to disclose material adverse facts about Boston Scientific’s prospects, operations, and business. Specifically, Boston Scientific failed to disclose to investors that: (1) It was clear that the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional, which threatened the entire product line’s continued viability; (2) Boston Scientific had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System as a result; and (3) positive statements made by Boston Scientific about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2021.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
